多西他赛对比监测用于中高危前列腺癌根治性放疗后的结果——来自前瞻性随机开放标签III期SPCG-13试验
SPCG-13试验将376例中高危前列腺癌患者随机分为多西他赛组(188例,放疗后接受6周期多西他赛75 mg/m2每3周一次、不加持续泼尼松)与监测组(188例),所有患者均接受新辅助/辅助雄激素剥夺治疗。中位随访59个月,两组生化无病生存曲线无差异(p=0.6),5年估计生化进展率多西他赛组31% vs 监测组28%。
要点
- 放疗加ADT后辅助多西他赛未改善中高危前列腺癌的生化无病生存。
- 多西他赛组发热性中性粒细胞减少发生率为16%,无治疗相关死亡。
- 多西他赛组与监测组5年估计生化进展率分别为31%与28%,曲线无差异(p=0.6)。
核心结论
- 在不加泼尼松的情况下,根治性放疗联合ADT后辅助多西他赛未能改善中高危前列腺癌患者的生化无病生存。
研究设计与样本
- 多国前瞻性随机开放标签III期试验,共随机376例患者,多西他赛组188例接受6周期多西他赛75 mg/m2每3周一次(不加持续泼尼松),监测组188例,均在放疗后;所有患者均接受新辅助/辅助ADT。
- 主要终点为前列腺特异性抗原(PSA)较最低值升高≥2 ng/ml;中高危定义为T2且Gleason评分4+3、PSA>10,或T2且Gleason评分8-10、PSA≤70 ng/ml,或任何T3。
- 随访5年,前2年每3个月评估PSA,之后每6个月评估一次。
主要发现
- 多西他赛组147例(78%)完成全部6周期治疗;两组中位年龄均为67岁,75%为T3期,47%为Gleason评分8-10。
- 中位随访59个月(范围1-111个月);多西他赛组58例、监测组57例观察到主要终点事件。
- Kaplan-Meier分析显示两组生化无病生存曲线无差异(p=0.6);5年估计生化进展率多西他赛组31% vs 监测组28%。
- 多西他赛组发热性中性粒细胞减少发生率为16%,无多西他赛治疗相关死亡。
- 试验期间共43例死亡,多西他赛组20例 vs 监测组23例,其中分别有9例和7例死于前列腺癌;Cox多变量分析中多西他赛组对比监测组PSA进展的风险比为1.14(95%置信区间0.79-1.64,p=0.5)。
关键数值与推荐
- 主要终点为PSA较最低值升高≥2 ng/ml。
- 中高危定义:T2且Gleason评分4+3、PSA>10;或T2且Gleason评分8-10、PSA≤70 ng/ml;或任何T3。
- 多西他赛方案为6周期75 mg/m2每3周一次,不加持续泼尼松。
- 研究把握度为89%,样本量计算考虑T2/T3分布,假定T2/T3患者生化无病生存差异为12%/15%。
临床怎么用
- 原文结论为辅助多西他赛未改善生化无病生存,未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Docetaxel combined with androgen deprivation therapy (ADT) has improved patient survival for advanced prostate cancer (PCa). OBJECTIVE: This randomised trial aimed to evaluate whether six courses of docetaxel improved biochemical disease-free survival (BDFS) after radical radiotherapy (RT) for intermediate- or high-risk PCa patients. DESIGN, SETTING, AND PARTICIPANTS: A total of 376 patients were randomised in this multinational phase III study, and received either six cycles of adjuvant docetaxel 75 mg/m2 every 3 wk without continuous prednisone (arm A, n = 188) or surveillance (arm B, n = 188) after RT (NTC006653848). Neoadjuvant/adjuvant ADT was mandatory for all the patients. The primary endpoint was rising prostate-specific antigen (PSA) ≥2 ng/ml above the nadir PSA value. Intermediate- or high-risk PCa was defined as T2 with a Gleason score (GS) of 4 + 3, PSA > 10; T2, GS 8-10, ≤ 70 ng/ml; or any T3. The patients were followed for 5 yr by assessing PSA levels every 3 mo for 2 yr and every 6 mo thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The study power was 89% to detect a difference in BDFS between groups, and the sample size calculation accounted for the T2/T3 distribution, where a 12%/15% difference in BDFS was assumed for the T2/T3 patients. RESULTS AND LIMITATIONS: All six cycles were completed in 147 (78%) of the patients in arm A. The median age was 67 yr in both treatment groups, 75% had T3 disease, and 47% had GS 8-10. The median follow-up was 59 mo (range 1-111 mo). The primary endpoint was observed for 58 patients in arm A (docetaxel) and for 57 patients in arm B (surveillance). The Kaplan-Meier analysis showed no difference in the BDFS curves (p = 0.6) between the treatment groups. The 5-yr estimated biochemical progression rates were 31% for arm A and 28% for arm B. Febrile neutropenia occurred in 16% of the docetaxel patients. No deaths were related to the docetaxel treatment. There were 43 deaths during the trial, including 20 in arm A and 23 in arm B, of which nine and seven, respectively, were due to PCa. The hazard ratio from Cox multivariate analysis for PSA progression of arm A (docetaxel) versus arm B (surveillance) was 1.14 (95% confidence interval 0.79-1.64, p = 0.5). CONCLUSIONS: Adjuvant docetaxel without prednisone did not improve BDFS after radical RT with ADT for intermediate- or high-risk PCa. PATIENT SUMMARY: We compared six cycles of adjuvant docetaxel given after radical external radiotherapy plus androgen deprivation therapy to surveillance in intermediate- and high-risk localised prostate cancer. We found no overall benefit in this setting.
引用
- Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, et al. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. Eur Urol. 2019. PMID: 31443961. doi:10.1016/j.eururo.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。